Log In
BCIQ
Print this Print this
 

RU-101

  Manage Alerts
Collapse Summary General Information
Company Sucampo Pharmaceuticals Inc.
DescriptionRecombinant human serum albumin
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationDry eye
Indication DetailsTreat dry eye; Treat severe dry eye disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$273.9M

$273.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/07/2015

$273.9M

$273.9M

0

Get a free BioCentury trial today